Tevogen Bio appoints former Citigroup and Morgan Stanley exec as head of investor relations and corporate development

Tevogen Bio Holdings Inc. on Wednesday announced it appointed Tapan Shah as head of investor relations and corporate development. Shah, a Wall Street veteran with over 25 years of experience across key financial services industry verticals, brings broad leadership capabilities to the Warren-based clinical biotech firm.

Shah will report directly to Tevogen Bio’s founder and CEO, Dr. Ryan Saadi.

In this new position, Shah will lead communications with all financial stakeholders, including shareholders, lenders, research analysts and investment bankers. He also will lead the mergers & acquisitions and capital raising functions at Tevogen Bio and be responsible for consolidating and analyzing inputs from key internal stakeholders to advise the executive leadership team on an appropriate course of action.

Most recently, Shah was director, relationship management, in Citigroup’s client organization, where he was also a member of the Executive Office. Prior to Citigroup, he worked in Morgan Stanley’s asset management business, focused on equity strategy and product development. Shah started his career in the Investment Banking Division of Goldman Sachs.

“Mr. Shah’s extensive background in financial services, paired with his ability to forge trusted adviser relationships, will steer our company through its upcoming stages of growth and play a crucial role as we venture into new areas of the health care ecosystem,” Saadi said.